2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1187

Chondroitin Sulfate/Glucosamine Hydrochloride Induce a Reduction in Adrenergic Serum Markers in Osteoarthritis Patients Similar to That Produced By Celecoxib
Abstract Number: 1102

Choosing Unwisely: HLA-B27 Testing and Adherence to Choosing Wisely Practices in a Large Integrated Academic Healthcare System
Abstract Number: 900

Choroid Plexus Tertiary Lymphoid Structures in Lupus: A Novel Neuro-Immune Interface
Abstract Number: 833

Chronic Cutaneous Lupus Erythematosus Patients Have a Breakdown in Autoreactive VH4.34 Antibody Tolerance While Maintaining Tolerance to dsDNA and Chromatin
Abstract Number: 401

Cigarette Smoking Dose-Dependently Facilitates the Onset of Arthritis and Aggravates Arthritis in Female Experimental Arthritis Mice
Abstract Number: 1844

Circulating Cytokine Profiles Reflect ANCA Specificity in Patients with ANCA-Associated Vasculitis
Abstract Number: 2143

Circulating Endothelial Cells and Endothelial Activation Markers As Disease Activity Measures in Idiopathic Inflammatory Myopathies
Abstract Number: 776

Circulating Fibrocytes in Systemic Sclerosis Patients and Healthy Subjects: An in Vitro Study
Abstract Number: 1367

Circulating Microbial Small RNAs Are Altered in Patients with Rheumatoid Arthritis
Abstract Number: 579

Circulating MiR-145 As a Marker of Therapeutic Response to Anti-TNF Therapy in Patients with Ankylosing Spondylitis
Abstract Number: 2435

Circulating Mirnas As Potential Biomarkers of Cardiovascular Disease in Rheumatoid Arthritis Patients
Abstract Number: 9L

Circulating Type I, II and III Interferons (IFNs) Associate with IFN-Scores, but Define Distinct Subsets of Active SLE
Abstract Number: 834

Citrulline-Polyspecific B Cell Antigen Receptors Arising from Somatic Hypermutation within Clades Demonstrate Pathogenicity in Rheumatoid Arthritis
Abstract Number: 82

CKD-506, a Novel Inhibitor of Histone Deacetylase 6 (HDAC6) Has a Therapeutic Potential in Rheumatoid Arthritis and Inflammatory Bowel Disease
Abstract Number: 1243

Clarifying Patient-Determined Barriers in Living with Systemic Lupus Erythematosus Treatment: A Qualitative Ethnographic Approach

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].